drugset / Trial / NCT01649050
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
Timeline
- Start
- 2016-10
- Primary completion
- 2018-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | selurampanel | Small molecule | — | Oral |
Indications
No indication recorded.